ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 85

Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America

Gulnara Mamyrova1, Takayuki Kishi2, Ira N Targoff3, Rodolfo V Curiel1, Frederick W Miller2, Lisa G Rider1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, 1Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, 2Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, 3VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: autoantibodies, juvenile dermatomyositis, outcomes and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Session Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis in Japanese pts. The aim of this study was to examine the frequency and characteristics of anti-MDA5 Abs associated with juvenile DM (JDM) in North America.        

Methods: Demographic, clinical, laboratory and outcome features of 37 pts with anti-MDA5 Abs were assessed and compared to those of 60 MSA/MAA negative and 175 anti-p155/140 Ab+ JDM and JCTM/DM pts meeting probable or definite Bohan and Peter criteria. Differences were evaluated by Fisher’s exact and Mann-Whitney tests. Kaplan-Meier and Log-rank tests were used for treatment analysis. Myositis Abs were tested by standard immunoprecipitation (IP) and MDA-5 and p155/140 Abs tested by reverse IP-immunoblot. Significant univariable results were examined in multivariable logistic regression.   

Results:   Anti-MDA5 Abs were identified in 37 (7.9%) pts out of a cohort of 467 JDM and JCTM/DM pts. Characteristics of MDA5+ pts compared to MSA/MAA- and anti-p155/140 Ab JDM and JCTM/DM pts are shown in the Table. MDA5 Ab+ pts had lower serum CK levels. MDA5 Ab+ pts more frequently had fatigue, fever, weight loss, adenopathy, arthralgia, arthritis, abnormal PFTs, dyspnea, and ILD compared to Ab- and p155/140+ pts. The median skeletal, pulmonary and constitutional symptom scores at diagnosis were higher in MDA5 Ab+ pts, but the median overall clinical symptom score at diagnosis was lower compared to Ab- and higher compared to p155/140+ pts (p<0.0001).  There were no differences in gender distribution, delay to diagnosis, and onset severity among the three groups.  Anti-MDA5 Ab + pts did not differ in total number or types of medications received, or in frequency of remission compared to MSA/MAA- or p155/140 Ab+ pts. MDA5+ pts had fewer flares (48% vs. 73%, p=0.014), and shorter time to final steroid discontinuation (30 [IQR 16-66] vs. 53 mths [IQR 26-128], p=0.009) compared to p155/140+ pts. Multivariable analysis revealed weight loss, arthritis and lower serum CK level were significantly associated with anti-MDA5+ vs Ab – pts, whereas, weight loss, arthritis, arthralgia, dyspnea, fever, and slow disease onset speed were significantly associated with anti-MDA5+ vs. p155/140+. There were no differences in disease course, status at most recent evaluation, ACR functional class, and mortality of MDA5+ vs either group.

Conclusion:  Anti-MDA5 Abs are seen in a distinct subset of juvenile myositis with JDM who have frequent arthritis, arthralgia, weight loss, adenopathy, and ILD, but lower serum CK. MDA5+ pts have comparable outcomes, but with the ability to discontinue steroids more rapidly and less frequent flares compared to p155/140+ pts.  

Table.  Characteristics of JDM patients with anti-MDA5 Abs compared to MSA/MAA negative and anti-p155/140 Ab

 

Anti-MDA5+

Median [IQ range] or

%

MSA/MAA Neg*

Median [IQ range] or

%

Anti-p155/140+*

Median [IQ range] or

%

Age at diagnosis (yr)

8.7 [6.4-12.9]

7.6 [5.3-11.4]

7.0 [4.2-10.9]1

Slow onset speed (3-6 mo)

48.6

36.2

22.33

ANA titer

40 [0-320]

40 [0-320]

320 [80-1280]4

Fatigue

94.6

80.0

82.9

Weight loss

81.1

28.84

32.04

Fever

64.9

43.3

30.34

Adenopathy

40.5

15.32

20.81

Constitutional System Score

0.5 [0.5-0.8]

0.25 [0.25-0.5]4

0.25 [0.25-0.5]4

Falling episodes

6 (16.7)

35.0 

36.81

Highest CK (≤ 252U/L)

182.0 [78.0-252.0]

745.5 [293.0-3029.0]4

438.5 [189.5-2017.0]4

Muscle System Score

0.29 [0.14-0.43]

0.29 [0.15-0.48]

0.29 [0.14-0.43]

Arthralgia

86.1

46.74

53.74

Arthritis

86.5

41.74

39.44

Skeletal System Score

0.5 [0.5-1.0]

0.0 [0.0-0.5]4

0.5 [0.0-0.5]4

Malar rash

62.2

65.0

89.74

V-sign

16.2

25.4

39.72

Periungual capillary abnormalities

83.8

63.21

87.3

Cuticular overgrowth

27.0

17.2

46.51

Cutaneous ulcers

29.7

16.7

20.0

Alopecia

5.4

0.0

1.7

Lipodystrophy

0.0

5.1

14.91

Cutaneous System Score

0.28 [0.17-0.37]

0.24 [0.14-0.33]

0.31 [0.22-0.39]

Abnormal PFT

32.3

10.91

22.3

Dyspnea on exertion

43.2

15.03

17.33

Interstitial lung disease

24.3

1.74

1.74

Pulmonary System Score

0.0 [0.0-0.2]

0.0 [0.0-0.0]1

0.0 [0.0-0.0]1

Dysphagia

16.2

35.6

35.41

Gastrointestinal ulceration

8.1

5.0

0.61

Gastrointestinal System Score

0.0 [0.0-0.1]

0.0 [0.0-0.0]

0.0 [0.0-0.11]

Overall/Total System Score

0.27 [0.22-0.34]

1.2 [0.87-1.8]4

0.20 [0.11-0.28]4

Chronic Disease Course

45.5

37.3

64.5

Mortality

2.7

3.3

1.1

 *Significant differences from anti-MDA5 Ab: 1p <0.05; 2 p<0.01; 3p <0.005; 4p < 0.001

Note that percentages may not reflect the number divided by the total number of subjects, if data missing  

 

 


Disclosure: G. Mamyrova, 2; T. Kishi, 2; I. N. Targoff, 5; R. V. Curiel, 2; F. W. Miller, None; L. G. Rider, 2.

To cite this abstract in AMA style:

Mamyrova G, Kishi T, Targoff IN, Curiel RV, Miller FW, Rider LG. Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/characteristics-of-anti-mda5-autoantibody-associated-juvenile-dermatomyositis-jdm-in-north-america/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-of-anti-mda5-autoantibody-associated-juvenile-dermatomyositis-jdm-in-north-america/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences